Učitavanje...
GlycoPEGylated recombinant factor IX for hemophilia B in context
Decisions over hemophilia treatment selection and switching involve balancing many clinical and patient-related factors. The current standard of care for patients with hemophilia B is prophylaxis with plasma-derived or recombinant factor IX (rFIX) concentrates. However, several extended half-life (E...
Spremljeno u:
| Izdano u: | Drug Des Devel Ther |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6141116/ https://ncbi.nlm.nih.gov/pubmed/30254423 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S121743 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|